Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Zacks News
Should You Buy the Dip in CRISPR Therapeutics?
by David Borun
A "Clinical Hold" from the FDA has the shares falling, but is it an opportunity to get in?
Vertex Pharmaceuticals (VRTX) Down 1.2% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Genome Editing the Next Biotech Breakthrough?
by David Borun
CRISPR technology is promising to be the foundation the treatment of 1000s of diseases
The Zacks Analyst Blog Highlights: General Dynamics, Enbridge, CSX, Humana and Vertex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: General Dynamics, Enbridge, CSX, Humana and Vertex
Top Research Reports for General Dynamics, Enbridge & CSX Corporation
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including General Dynamics (GD), Enbridge (ENB) and CSX Corporation (CSX).
Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1
by Zacks Equity Research
The biotech sector was in focus over the last five trading sessions as several bigwigs like Gilead and Vertex, among others reported results while some others provided pipeline updates.
Vertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales
by Zacks Equity Research
Vertex Pharma (VRTX) first-quarter earnings increase from the year-ago period led by strong sales trend of CF drugs.
Is a Beat in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
Vertex (VRTX) is expected to beat estimates when it reports its Q1 earnings on Apr 26.
Why Earnings Season Could Be Great for Vertex Pharmaceuticals (VRTX)
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
Pharma M&A Active This Week: 4 Potential Buyout Targets
by Indrajit Bandyopadhyay
Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
Is PowerShares Dynamic Biotechnology & Genome Portfolio (PBE) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Top Research Reports for Oracle, Vale & General Mills
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Vale (VALE) and General Mills (GIS).
3 Biotech Stocks With Rising Earnings Estimates Post Q4
by Zacks Equity Research
The biotech industry performed reasonably well in Q4. Hence, it is a good idea to select stocks from the sector which saw positive estimate revisions post Q4 earnings release.
Biotech Stock Round Up: Celgene Suffers Setback, Gilead Teams Up with Sangamo
by Zacks Equity Research
The major news in the biotech sector in the last five trading sessions include the FDA's refusal to file letter for Celgene Corporation's (CELG) ozanimod while Gilead Sciences, Inc.'s (GILD) announced an agreement with Sangamo Therapeutics.
The Zacks Analyst Blog Highlights: Amgen, TOTAL, Marriott, PG&E and Vertex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, TOTAL, Marriott, PG&E and Vertex
Top Analyst Report for Amgen, TOTAL S.A. & Marriott
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), TOTAL S.A. (TOT) and Marriott (MAR).
Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval
by Zacks Equity Research
Vertex???s (VRTX) FDA approved tezacaftor/ivacaftor combination for cystic fibrosis in patients with certain mutations in the CFTR gene marks the indication???s third treatment.
The Zacks Analyst Blog Highlights: Wells Fargo, Caterpillar, Schlumberger, Vertex and Republic Services
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Wells Fargo, Caterpillar, Schlumberger, Vertex and Republic Services
REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings?
by Zacks Equity Research
Let's take a look at which of these biotech companies, Alexion (ALXN) or Regeneron (REGN) has an edge ahead of their Q4 release.
Top Stock Reports for Wells Fargo, Caterpillar & Schlumberger
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), Caterpillar (CAT) and Schlumberger (SLB).
The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex
Vertex (VRTX) Q4 Earnings Beat on Strong CF Products Sales
by Zacks Equity Research
Vertex Pharma (VRTX) fourth-quarter earnings increase from the year-ago period led by strong sales of CF drugs and lower operating expenses.
Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi
by Arpita Dutt
While companies like AbbVie (ABBV) were in focus on 4Q earnings results, Ablynx was in the news with the company agreeing to be acquired by French pharma giant, Sanofi.
Vertex (VRTX) & Other Drug Stocks with FDA Catalysts this February
by Arpita Dutt
Here is a look at Vertex (VRTX) and a few other companies that await a decision from the FDA in February for label expansions or new drugs.